Establishment and characterization of clear cell renal cell carcinoma cell lines with different metastatic potential from Chinese patients

Cancer Cell International

Guangwen Cao⁵  Jianguo Hou¹  Tong Su⁵  Jianhua Yin⁵  Wenjun Chang⁵  Yan Du⁵  Guoping Wang⁵  Danfeng Xu⁴  Jianru Xiao²  Yongwei Yu³  Yifang Han⁵  Songqin He⁵  Xiaojie Tan⁵ 

[1] Department of Urology, the 1st Affiliated Hospital, Second Military Medical University, Shanghai, China;Department of Orthopaedics Surgery, the 2nd Affiliated Hospital, Second Military Medical University, Shanghai, China;Department of Pathology, the 1st Affiliated Hospital, Second Military Medical University, Shanghai, China;Department of Urology, the 2nd Affiliated Hospital, Second Military Medical University, Shanghai, China;Department of Epidemiology, Second Military Medical University, 800 Xiangyin Rd, Shanghai 200433, China

关键词: Chinese;    Metastasis;    Cell line;    Clear cell;    Renal cell carcinoma;   

Others  :  794276
DOI  :  10.1186/1475-2867-13-20

 received in 2012-08-15, accepted in 2012-12-19,  发布年份 2013

【 摘 要 】

s

Background

Clear cell renal cell carcinoma (ccRCC) cell lines with distinct metastatic potential are essential to study the mechanism of ccRCC metastasis. However, none of them originated from Chinese.

Methods

Primary cell cultures were performed using a primary tumor of a 49-year-old male ccRCC patient and a metastatic tumor of a 62-year-old male patient who had received nephrectomy to excise primary ccRCC 10 years ago. Cell growth, microstructure, cytogenetics, cytometry, expression of metastasis-associated molecules, tumorigenesis and metastasis were subsequently characterized.

Results

Two successive cell lines named NRCC from the primary ccRCC and MRCC from the metastatic ccRCC were established, respectively. Compared to NRCC, MRCC exhibited stronger anchorage-independent growth and invasion potentials and contained more glycogen granules in the cytoplasm. Gains of chromosomes and some translocations were the major chromosomal aberrations in both cell strains. CD24 expression was more frequent in MRCC than in NRCC and the same was true for CD56. The transcriptional levels of TNFα, IL-6, VEGF, HIF2α, MMP2, and RhoC were significantly higher in MRCC than in NRCC. Cytosolic IκBα protein was more degraded in MRCC than in NRCC following TNFα treatment. Both cell lines had strong tumorigenicity in athymic nude mice. However, MRCC had strong potential in generating metastasis to lung and hemorrhagic ascites than NRCC following orthotopic transplantations.

Conclusions

Cancer cells isolated from metastatic ccRCC have more malignant and metastatic potential than those from the primary tumor from the patients who shared the similar race background. Establishment of MRCC and NRCC may provide suitable models with which to investigate molecular mechanisms of ccRCC metastasis.

【 授权许可】

   
2013 Tan et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol 2011, 60:615-621.
• [2]Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, de Kernion JB, Figlin RA, Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002, 20:4559-4566.
• [3]Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, ARCCS Study Investigators: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116:1272-1280.
• [4]Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, Angevin E, Caignard A: Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 2004, 109:393-401.
• [5]Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group:: : Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
• [6]Wang G, Hou J, Ma L, Xie J, Yin J, Xu D, Chang W, Tan X, Su T, Zhang H, Cao G: Risk factor for clear cell renal cell carcinoma in Chinese population: a case–control study. Cancer Epidemiol 2012, 36:177-182.
• [7]Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 1986, 46:4109-4115.
• [8]Yano H, Maruiwa M, Sugihara S, Kojiro M, Noda S, Eto K: Establishment and characterization of a new human renal cell carcinoma cell line (KRC/Y). In Vitro Cell Dev Biol 1988, 24:9-16.
• [9]Krishnan B, Truong LD: Renal epithelial neoplasms: the diagnostic implications of electron microscopic study in 55 cases. Hum Pathol 2002, 33:68-79.
• [10]Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G: Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 2008, 22:3696-3705.
• [11]Medina Villaamil V, Aparicio Gallego G, Valbuena Rubira L, García Campelo R, Valladares-Ayerbes M, Grande Pulido E, Victoria Bolós M, Santamarina Caínzos I, Antón Aparicio LM: Fructose transporter GLUT5 expression in clear renal cell carcinoma. Oncol Rep 2011, 25:315-323.
• [12]Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 1990, 9:2431-2438.
• [13]Varga Z, Caduff R: Glycogen-rich carcinomas of the breast display unique characteristics with respect to proliferation and the frequency of oligonucleosomal fragments. Breast Cancer Res Treat 1999, 57:215-219.
• [14]Steiner G, Sidransky D: Molecular differential diagnosis of renal carcinoma: from microscopes to microsatellites. Am J Pathol 1996, 149:1791-1795.
• [15]Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE: Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 2009, 15:7582-7592.
• [16]Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H, He W, Zeng L, Xing M, Wu R, Jiang H, Liu X, Cao D, Guo G, Hu X, Gui Y, Li Z, Xie W, Sun X, Shi M, Cai Z, Wang B, Zhong M, Li J, Lu Z, Gu N: Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012, 148:886-895.
• [17]Chi A, Shirodkar SP, Escudero DO, Ekwenna OO, Yates TJ, Ayyathurai R, Garcia-Roig M, Gahan JC, Manoharan M, Bird VG, Lokeshwar VB: Molecular characterization of kidney cancer: Association of hyaluronic acid family with histological subtypes and metastasis. Cancer 2012, 118:2394-2402.
• [18]D’Alterio C, Cindolo L, Portella L, Polimeno M, Consales C, Riccio A, Cioffi M, Franco R, Chiodini P, Cartenì G, Mirone V, Longo N, Marra L, Perdonà S, Claudio L, Mascolo M, Staibano S, Falsaperla M, Puglisi M, Martignoni G, Ficarra V, Castello G, Scala S: Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 2010, 9:4492-4500.
• [19]Lee HJ, Kim DI, Kwak C, Ku JH, Moon KC: Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance. Urology 2008, 72:603-607.
• [20]Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G: Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 2012, 48:1977-1987.
• [21]Daniel L, Bouvier C, Chetaille B, Gouvernet J, Luccioni A, Rossi D, Lechevallier E, Muracciole X, Coulange C, Figarella-Branger D: Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior. Hum Pathol 2003, 34:528-532.
• [22]Ho A, Fusenig N: Cancer stem cells: a promising concept and therapeutic challenge. Int J Cancer 2011, 129:2309.
• [23]Cabarcas SM, Mathews LA, Farrar WL: The cancer stem cell niche–there goes the neighborhood? Int J Cancer 2011, 129:2315-2327.
• [24]Fukata S, Inoue K, Kamada M, Kawada C, Furihata M, Ohtsuki Y, Shuin T: Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer 2005, 103:931-942.
• [25]Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP: Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer 2012, 130:2693-2702.
• [26]Abe H, Kamai T, Tsujii T, Nakamura F, Mashidori T, Mizuno T, Tanaka M, Tatsumiya K, Furuya N, Masuda A, Yamanishi T, Yoshida K: Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma. Biomed Res 2008, 29:155-161.
• [27]Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, Cha TL, Sun GH: Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008, 99:905-913.
• [28]Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, Charles K, Ahern R, King DM, Eisen T, Corringham R, DeWitte M, Balkwill F, Gore M: Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007, 25:4542-4549.
• [29]Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC: HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007, 11:335-347.
• [30]Choi H, Chun YS, Kim TY, Park JW: HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin. Cancer Res 2010, 70:10101-10111.
• [31]Sourbier C, Danilin S, Lindner V, Steger J, Rothhut S, Meyer N, Jacqmin D, Helwig JJ, Lang H, Massfelder T: Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 2007, 67:11668-11676.
• [32]Tan X, Zhai Y, Chang W, Hou J, He S, Lin L, Yu Y, Xu D, Xiao J, Ma L, Wang G, Cao T, Cao G: Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma. Int J Cancer 2008, 123:1080-1088.
• [33]Rumpler Y, Andriaholinirina N, Warter S, Hauwy M, Rabarivola C: Phylogenetic history of the Sifakas (Propithecus: Lemuriformes) derived from cytogenetic studies. Chromosome Res 2004, 12:453-463.
• [34]Li X, Tan X, Yu Y, Chen H, Chang W, Hou J, Xu D, Ma L, Cao G: D9S168 microsatellite alteration predicts a poor prognosis in patients with clear cell renal cell carcinoma and correlates with the down-regulation of protein tyrosine phosphatase receptor delta. Cancer 2011, 117:4201-4211.
• [35]Sun W, Tan X, Shi Y, Xu G, Mao R, Gu X, Fan Y, Yu Y, Burlingame S, Zhang H, Rednam SP, Lu X, Zhang T, Fu S, Cao G, Qin J, Yang J: USP11 negatively regulates TNFalpha-induced NF-kappaB activation by targeting on IkappaBalpha. Cell Signal 2010, 22:386-394.
• [36]An Z, Jiang P, Wang X, Moossa AR, Hoffman RM: Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection. Clin Exp Metastasis 1999, 17:265-270.